Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient Experience with Octreotide LAR vs Lanreotide in NETs
NCT03289741Phase 4Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2017
- Primary completion
- Apr 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of octreotide, lanreotide in neuroendocrine tumors (NETs), sponsored by Memorial Sloan Kettering Cancer Center. Started Sep 2017; status: completed.
02
Drugs
octreotidelanreotide
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT03289741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03289741.